ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.
about
Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancerHistone deacetylase inhibition induces long-lasting changes in maternal behavior and gene expression in female miceExperience-facilitated improvements in pup retrieval; evidence for an epigenetic effectAcquisition of sexual receptivity: roles of chromatin acetylation, estrogen receptor-alpha, and ovarian hormones.Specific activity of class II histone deacetylases in human breast cancer cellsManipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Acetylation and nuclear receptor actionTamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sitesDifferential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the BreastPhosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor betaChemokines: novel targets for breast cancer metastasisTamoxifen resistance and epigenetic modifications in breast cancer cell linesThe silent estrogen receptor--can we make it speak?Activation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells.EF24 prevents rotenone-induced estrogenic status alteration in breast cancer.Functional genomic methods to study estrogen receptor activity.Neuroprotective effects of a chromatin modifier on ischemia/reperfusion neurons: implication of its regulation of BCL2 transactivation by ERα signaling.Inhibitory effects of ERβ on proliferation, invasion, and tumor formation of MCF-7 breast cancer cells--prognostication for the use of ERβ-selective therapy.The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression.Targeting triple negative breast cancer with histone deacetylase inhibitors.Role of ghrelin on estrogen and progesterone secretion in the adult rat ovary during estrous cycle.PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression.Histone deacetylase inhibitor treatment induces postpartum-like maternal behavior and immediate early gene expression in the maternal neural pathway in virgin mice.Liposomal trichostatin A: therapeutic potential in hormone-dependent and -independent breast cancer xenograft models.
P2860
Q27319512-C06C113B-691A-44BC-A33C-DC6FEE950FA6Q30371084-2593DCE2-6FF5-42E7-A347-08591761D675Q30418499-C3792CFF-54F9-4E41-9EE4-BC9F55CE5392Q30425720-CB60CA67-33A7-4F60-BD9E-A05FF4EE2072Q33606021-8B0D83DF-DC6E-4E72-AF35-9D196745F30AQ34417159-EAD609A5-E7F0-45A4-887D-6A083C5D1581Q34488424-436E7DB8-F93E-4AB6-9C40-A1E40AE86575Q34666075-D847A5FB-30C4-4686-B5F9-9C7FF9BB7CB4Q34682354-587A116D-31E3-4572-98C1-A1EF61EB86CBQ34693969-D89A4D27-F6AF-4D74-8EAB-4F7687C83EABQ34779627-45D241BA-3575-4E13-925B-A791B172FA31Q36593555-B3C07434-8152-48D9-AC63-6CB7B1425AFAQ36918688-5F2AD130-3D61-440E-93D7-4C7F764516D7Q37066053-637E8498-FF04-43BB-9951-494B4B418B31Q37468213-A62B2241-A565-4B30-BD21-36CC3D47C1EAQ37521175-DE2D8A16-23C4-4348-879B-EB3A0F12CB3CQ37633353-7577DA01-C3A7-4CB2-AF82-A3A6F45243A4Q38010345-0492B63F-499C-4C8B-8F35-555742F265FAQ38806745-48EF1816-F589-44F9-AF8C-84A3D745BF11Q39367554-F72ADA76-6CBB-4156-A503-B125805929D9Q39369222-DB0880CA-3A2F-4E99-878D-7256A46F0B1AQ47927498-0ABE1549-2A9B-4B06-9D5B-309DD68881ABQ48799759-C2FDA8E1-53C0-46E3-89A5-668B540C2A1CQ49152068-C6098B9C-D345-4637-A4C5-7297294811B7Q52676985-40806C61-B553-4CE1-BF6C-ABA2EB49E6D7Q53251316-66CF9A82-520F-4CA0-B86E-0F7C4AF89659
P2860
ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
ERalpha and ERbeta expression ...... regulated by HDAC inhibitors.
@ast
ERalpha and ERbeta expression ...... regulated by HDAC inhibitors.
@en
type
label
ERalpha and ERbeta expression ...... regulated by HDAC inhibitors.
@ast
ERalpha and ERbeta expression ...... regulated by HDAC inhibitors.
@en
prefLabel
ERalpha and ERbeta expression ...... regulated by HDAC inhibitors.
@ast
ERalpha and ERbeta expression ...... regulated by HDAC inhibitors.
@en
P2093
P2860
P356
P1433
P1476
ERalpha and ERbeta expression ...... y regulated by HDAC inhibitors
@en
P2093
B S Katzenellenbogen
G Lazennec
P2860
P2888
P304
P356
10.1038/SJ.ONC.1209102
P407
P577
2006-03-01T00:00:00Z